Autoaggressive T H cells can induce tissue damage and inflammation and are believed to be crucial in the pathogenesis of various immune diseases 1, 2 . Recent studies suggest that, among the three effector T H subsets (T H 1, T H 2 and T H 17), T H 17 cells or both T H 1 and T H 17 cells mediate tissue damage, inflammation and autoimmunity [1] [2] [3] [4] [5] . T H 1 and T H 17 cells are characterized by their expression of interferon-g (IFN-g) and interleukin-17 (IL-17), respectively. T H 1 differentiation is induced by IL-12, and T H 17 differentiation is induced by transforming growth factor-b (TGF-b) and IL-6 and is expanded by IL-23. Notably, IL-12 and IL-23 share the common p40 subunit. Gene disruption or inhibition of cytokines such as IL-17, IL-12 and IL-23 suppresses the development and progression of pathological processes in various mouse models of human diseases, including experimental autoimmune encephalomyelitis (EAE), collagen-induced arthritis, experimental colitis and contact hypersensitivity (CHS) [1] [2] [3] [4] [5] . Involvement of the T H 1 and T H 17 subsets in human diseases is further supported by accumulation of these T H cells and upregulation of expression of their signature cytokines, IL-17, IFN-g or p40, in the brain and peripheral blood mononuclear cells of individuals with multiple sclerosis [6] [7] [8] [9] , the synovial fluid of individuals with rheumatoid arthritis 10 , the gut of individuals with Crohn's disease 11, 12 and the skin of individuals with psoriasis 13 , and by the association of particular genetic variants with disease susceptibility, as exemplified by an IL-23 receptor gene single-nucleotide polymorphism in Crohn's disease 14, 15 and by variants of the IL-23 receptor or IL-12 genes in psoriasis 16 . Therefore, one drug development strategy for these diseases could be the manipulation of these cytokines and their actions. Indeed, clinical trials targeting these cytokines (for example, with monoclonal antibody to p40) in individuals with Crohn's disease 17 and psoriasis 18 have already been carried out with some beneficial effects. However, pharmacological measures interfering with generation or expansion of these effector T H cells, if found, would be an alternative or even better therapeutic intervention. Although the cytokine-directed pathways mentioned above constitute the basic frameworks for development of T H 1 and T H 17 subsets [1] [2] [3] [4] [5] , the polarization of the T cell response in vivo may be influenced and boosted by noncytokine substances in the local inflammatory milieu.
One candidate for these noncytokine substances is the prostanoid family of lipid mediators. Prostanoids, including PGD 2 , PGE 2 , PGF 2a , PGI 2 and thromboxane A 2 , are produced from arachidonic acid in response to various stimuli by the sequential actions of cyclooxygenase and the respective synthases and are abundant at inflammation sites 19 . Among prostanoids, PGE 2 has long been known as an immunomodulatory substance that suppresses T H 1 differentiation by raising intracellular cyclic AMP (cAMP) concentrations [20] [21] [22] [23] [24] [25] . PGE 2 acts on four subtypes of G protein-coupled receptors termed EP1, EP2, EP3 and EP4, among which EP2 and EP4 signaling is coupled to a rise in cAMP concentration 19, 26 . A recent study 27 used T cells deficient in each EP subtype and found that the immunosuppressive action of PGE 2 is mediated by both EP2 and EP4. However, T cell suppression by PGE 2 has been shown mostly in vitro and is rarely seen in vivo in intact animals, raising the possibility that PGE 2 acts differently in in vivo immune responses. Given the current awareness that T cell receptor (TCR) signals can antagonize growth suppression by cAMP in T cells 28 and that immune inflammation is exerted by the actions of both T H 1 and T H 17 cells, we have reexamined the in vitro effects of PGE 2 on T H 1 differentiation, examined those on T H 17 differentiation and expansion, and investigated the impact of these PGE 2 actions on immune inflammation in vivo.
RESULTS

PGE 2 promotes T H 1 cell differentiation through EP2 and EP4
We isolated CD4 + CD62L (L-selectin) + naive T cells from the spleens of C57BL/6 mice and incubated them with various concentrations of PGE 2 under T H 1-skewing conditions with TCR stimulation of various strengths. When we stimulated the TCR with 10 mg ml À1 of antibody to CD3 and 0 mg ml À1 or 2.5 mg ml À1 of antibody to CD28, PGE 2 treatment increased the mean fluorescence intensity for IFN-g in a concentration-dependent manner and induced a significant increase in the percentage and number of IFN-g + T H 1 cells at 1 nM PGE 2 (Fig. 1a,b ). However, such T H 1 differentiation-promoting activity was lost at higher PGE 2 concentrations, at which a concentration-dependent decrease in the total cell number was observed (Fig. 1b) . These findings led us to hypothesize that PGE 2 exerted the well-known T H 1 suppression at higher concentrations and this masked its T H 1 differentiation-promoting activity at lower concentrations. We therefore examined the effects of PGE 2 on T H 1 differentiation with 10 and 100 mg ml À1 of antibody to CD28 (ref. 29) . With these strengthened CD28 stimulations, PGE 2 significantly enhanced T H 1 differentiation at nanomolar concentrations; we observed about a threefold increase in the number of T H 1 cells at 1 nM PGE 2 for the 3-d culture (Fig. 1a,b) . This PGE 2 effect was more evident for the 4-d culture: significantly more IFN-g producing cells were induced by PGE 2 at 10 mg ml À1 each of antibodies to CD3 and CD28 (P o 0.05) ( Supplementary Fig. 1 online). We also found similar effects of PGE 2 in T cells from BALB/c mice ( Supplementary Fig. 2 online). Without IL-12, PGE 2 had few effects on T H 1 differentiation (data not shown), suggesting that PGE 2 enhances the action of IL-12. We next used agonists selective for each EP subtype 26, 30, 31 . We found that both EP2-selective and EP4-selective agonists, ONO-AE1-259 and ONO-AE1-329, respectively, increased T H 1 differentiation in a concentration-dependent manner, whereas agonists selective for EP1 and EP3, ONO-DI-004 and ONO-AE-248, respectively, did not have an effect (Fig. 1c) . The effect of the EP4 agonist was suppressed by the addition of an EP4-selective antagonist, ONO-AE3-208 (ref. 32 ; Fig. 1d ) and was absent in T cells from EP4-deficient (Ptger4 À/À ) mice 33 ( Fig. 1e) . Similarly, the effect of the EP2 agonist was absent in T cells from EP2-deficient (Ptger2 À/À ) mice 34 ( Fig. 1f) .
The above results indicate, in contrast to previous studies [21] [22] [23] [24] [25] [26] 28 , that EP2 and EP4 receptors facilitate T H 1 differentiation. Given that EP2 and EP4 share a rise in cAMP as a downstream signal, we examined the involvement of cAMP in the effect of PGE 2 on T H 1 EP2 agonist EP4 agonist differentiation. However, the action of EP2 and EP4 was neither mimicked by cAMP analogs 35 ( Fig. 2a) nor attenuated by inhibitors of protein kinase A (PKA) 36 (Fig. 2b) . In contrast, both EP2-and EP4-mediated T H 1 differentiation was inhibited by the phosphoinositide 3-kinase (PI3K) inhibitors 37 wortmannin and LY294002 (Fig. 2c) . Whereas EP4 couples to PI3K activation via b-arrestinc-Src signaling 38 , EP2 is resistant to agonist-induced desensitization 39 and is believed not to couple to b-arrestin. We therefore examined the effects of EP2 stimulation on PI3K activation, which we read out as Akt phosphorylation in T cells. CD3 and CD28 stimulation alone induced activation of PI3K as reported previously 40 . However, the addition of either EP4 agonist or EP2 agonist increased Akt phosphorylation in naive T cells in a concentration-dependent manner additive to TCR stimulation, and these responses were absent in T cells from mice deficient in either receptor (Fig. 2d) . Coupling of EP2 and EP4 to PI3K was further confirmed by analysis in HEK293 cells expressing recombinant mouse EP2 or mouse EP4 receptor (Fig. 2e) . Thus, opposite to the current belief 25, 27 , EP2 and EP4 signaling facilitates T H 1 differentiation at physiological nanomolar concentrations through PI3K signaling. Supplementary Fig. 3a online) . Furthermore, PGE 2 did not substantially affect T H 2 differentiation and suppressed regulatory T cell differentiation in a concentration-dependent manner ( Supplementary Fig. 3b,c) . Thus, facilitation of T cell differentiation by PGE 2 is specific to the T H 1 subset. IL-23 that stimulates T H 17 expansion is produced by activated dendritic cells (DCs) [1] [2] [3] 41 . We prepared CD11c + DCs from the spleens of C57BL/6 mice and examined the effects of PGE 2 on IL-23 production by DCs. Activation of the DCs with antibody to CD40 resulted in production of a significant amount of IL-23 (Fig. 3a) . The addition of PGE 2 enhanced IL-23 production, which was mimicked by the EP4 agonist (Fig. 3a) . The EP1 and EP3 agonists had no effects, and the EP2 agonist showed variable effects (data not shown). Notably, addition of the EP4 antagonist not only blocked the EP4 agonistmediated enhancement but also almost completely suppressed the IL-23 production by DCs (Fig. 3a) , indicating the presence and action of endogenous PGE 2 . Quantification by ELISA revealed that PGE 2 was present in a significant amount in this DC culture, and the amount was slightly enhanced by CD40 stimulation (Fig. 3b) . Treatment of DCs with indomethacin, an inhibitor of PG synthesis, inhibited PGE 2 production and suppressed IL-23 production almost completely, and addition of exogenous PGE 2 fully recovered the IL-23 production (Fig. 3b,c) . These results indicate that endogenous PGE 2 is required for IL-23 production by DCs stimulated with antibody to CD40. This action of EP4 activation was mimicked by dibutyryl cAMP (db-cAMP) and an agonist specific to exchange protein directly activated by cAMP (Epac), 8-pCPT-2¢-O-Me-cAMP, and was insensitive to a PKA inhibitor, H-89, and to the PI3K inhibitors (Fig. 3d,e) . These results suggest that the induction of IL-23 in DCs requires PGE 2 -EP4 signaling and is dependent on the cAMP-Epac pathway.
CD40 stimulation also enhanced IL-12 production in DCs (Supplementary Fig. 4 online) . In contrast to IL-23 production, addition of PGE 2 or the EP4 agonist at 100 nM tended to suppress the production of IL-12 by splenic DCs activated by antibody to CD40 ( Supplementary Fig. 4) . However, treatment of the cells with indomethacin or EP4 antagonist showed little effect on IL-12 production, indicating that endogenous PGE 2 has no regulatory role in IL-12 production by splenic DCs.
EP2 and EP4 facilitate IL-23-induced T H 17 cell expansion
We next examined the effects of PGE 2 on IL-23-induced T H 17 expansion. We incubated total CD4 + T cells from spleens with IL-23 in the presence of various PGE 2 concentrations. Under these conditions, IL-23 alone induced only a limited, about twofold, expansion of T H 17 cells (Fig. 4a) . Addition of PGE 2 enhanced the effects of IL-23 in a concentration-dependent fashion, with the number of T H 17 cells (Fig. 4a) and IL-17 production (Fig. 4b) increasing four-and sevenfold, respectively. Next, we first differentiated T H (Fig. 4c,d ). The number of IL-17-producing cells was expanded by IL-23 in the presence of TGF-b and IL-6 (Fig. 4c,d) . This is consistent with recent work showing that T H 17 cells require TGF-b for sustained expression of IL-17 and that IL-23 alone suppresses IL-17 expression in the absence of TGF-b 42, 43 . Notably, PGE 2 treatment alone maintained the number of IL-17-producing cells and markedly expanded both the number and the percentage of IL-17-producing cells in the presence of IL-23 (Fig. 4c,d) . These results show that PGE 2 potently stimulates IL-23 action on T H 17 expansion.
When we used various selective EP agonists, the EP2 and EP4 agonists mimicked the effect of PGE 2 on T H 17 expansion (Fig. 5a and Supplementary Fig. 5a online) , and the action of each EP-specific agonist was absent in T cells from mice deficient in the respective EP receptor (Fig. 5b,c) . In contrast to T H 1 differentiation, PGE 2 -induced T H 17 expansion was mimicked by db-cAMP and a PKA-specific agonist, N 6 -Bnz-cAMP ( Fig. 5d and Supplementary Fig. 5b) , was inhibited by H-89, a PKA inhibitor, and Rp-8-Br-cAMPS and Rp-8-CPT-cAMPS, type I and type II PKA inhibitors, respectively, (Fig. 5e) , and was insensitive to the PI3K inhibitors (Fig. 5f ).
EP4 antagonism suppresses CHS and EAE
To test whether PGE 2 regulates T H 1 and T H 17 cells in vivo as seen in vitro, we used two disease models, CHS 44 and EAE 45 , in which both T H 1 and T H 17 cells are involved in pathogenesis. In CHS, we immunized mice by painting dinitrofluorobenzene on the shaved abdomen on day 0 and challenged them on day 5 by painting the same antigen on the ear. We assessed immune inflammation by ear thickness 1 d later. Given that the loss of EP4 interferes with Langerhans cell migration 46 , we did not use Ptger4 À/À mice but administered the EP4 antagonist ONO-AE3-208 to wild-type (WT) mice starting 24 h after the immunization and examined Agonist (1 µM) its effect on immune response and T cell activation and differentiation. Administration of the EP4 antagonist into WT mice inhibited inflammation in the challenged ear in a dosedependent fashion (Fig. 6a) , suppressed T cell activation (Fig. 6b) and decreased production of IFN-g and IL-17 by lymph node cells (Fig. 6c) . These results suggest that EP4 antagonism inhibits development of both T H 1 and T H 17 cells in regional lymph nodes and suppresses the immune response. Notably, there was no augmentation of the EP4 antagonist-induced suppression in Ptger2 À/À mice (Fig. 6a) .
In EAE, we immunized mice with myelin oligodendrocyte glycoprotein (MOG) on day 0 and injected pertussis toxin on day 0 and day 2, and then we monitored progression of the disease 47 . We did not see any change in the onset and progression of EAE in Ptger2 À/À mice (Y.E., unpublished data), and administration of ONO-AE3-208 at 100 mg per kg body weight per day, in WT mice from day 3 to day 12 after MOG immunization almost completely suppressed disease development (Fig. 6d) . To examine the effect of the EP4 antagonist on antigen-dependent T cell differentiation, we administered the EP4 antagonist from day 3 to day 7 after MOG immunization, and dissected lymph nodes on day 7 for analysis. Lymph node cells from the mice treated with the EP4 antagonist showed significantly suppressed proliferation (Fig. 6e) and impaired production of IFN-g and IL-17 in response to MOG compared with control mice (Fig. 6f) . Thus, the results of both CHS and EAE experiments suggest that PGE 2 -EP4 signaling regulates T H 1 and T H 17 cell differentiation and expansion in in vivo immune responses.
DISCUSSION
Immune inflammation caused by pathogenic T H cells underlies a variety of immune diseases [1] [2] [3] [4] [5] , to which specific pharmacological measures are in demand. Here we have found that selective blockade of PGE 2 -EP4 signaling effectively suppresses disease progression of EAE and CHS, mouse models for multiple sclerosis and skin allergy. We have found three in vitro actions of this signaling on immune cells, which may underlie the effect of EP4 antagonism in vivo. First, we have found that PGE 2 through EP2 and EP4 facilitates T H 1 differentiation. This is opposite to the previous findings that PGE 2 suppresses T H 1 differentiation via these receptors in vitro and therefore should elicit immunosuppression in vivo [20] [21] [22] [23] [24] [25] 27 . Notably, we have obtained our results in conditions in which TCR stimulation was strengthened. Such findings, together with the fact that the EP2-and EP4-mediated immunosuppression is rarely seen in vivo, suggest that TCR stimulation in vivo can be stronger than currently thought. Second, we have observed that PGE 2 uses the same subtypes of PGE receptor, EP2 and EP4, and facilitates IL-23-induced T H 17 expansion. It should be noted that the T H 1-differentiating action of EP2 and EP4 is mediated by PI3K and not cAMP, and the T H 17-expanding action of EP2 and EP4 is mediated by cAMP and not PI3K. Thus, these two PGE 2 actions are exerted through different signaling modules of EP2 and EP4. Third, we have found that the PGE 2 -EP4 pathway is required for production of IL-23 by DCs activated with antibody to CD40. As PGE 2 itself cannot induce IL-23 production, PGE 2 action can be permissive for IL-23 induction by activated DCs. Previously, other researchers activated bone marrow-derived DCs with lipopolysaccharide and found that exogenously applied PGE 2 can augment IL-23 production by about twofold 48, 49 . They, however, did not examine the role of endogenous PGE 2 in IL-23 production by activated DCs. Here we activated splenic DCs with antibody to CD40 and revealed the role of endogenous PGE 2 . Given that stimulation with antibody to CD40 mimics the interaction of CD40 ligand on activated T cells with CD40 on DCs, these results suggest that PGE 2 is formed and functions during in vivo T cell-DC interactions in lymph nodes. Previously, we observed that DCs expressing PGE synthase increase in number in regional lymph nodes after antigen exposure 50 . This PGE 2 action on IL-23 production is through the EP4-cAMP-Epac pathway 51 , thus further adding complexity to EP4 signaling in immune responses. How this signaling regulates IL-23 production, how EP2-and EP4-PI3K signaling regulates T H 1 differentiation and how EP2-and EP4-cAMP-PKA signaling is involved in T H 17 expansion are all questions that concern how G protein-coupled receptor signaling interacts with cytokine and co-stimulation signaling.
Given the redundant in vitro actions of EP2 and EP4 on T cells, we found it rather surprising that administration of the EP4 antagonist alone significantly suppressed CHS and EAE. Consistent with our results, an EP4 antagonist with a different structure can also suppress progression of mouse EAE by inhibiting T H 1 and T H 17 cell differentiation and expansion (Q. Chen and M. Lamphier (Eisai Research Institute), personal communication), suggesting that in addition to its action on IL-23 production, EP4 functions nonredundantly in vivo. The gene encoding human EP4 was assigned as a susceptibility gene of Crohn's disease 15, 52 , in which involvement of IL-23 and T H 17 is indicated 53 .
Prostanoids, including PGE 2 , have traditionally been believed to have little function in adaptive immunity, because nonsteroidal antiinflammatory drugs that inhibit prostanoid synthesis show little effect on immune responses. However, as shown here, studies using mice deficient in various prostanoid receptors and highly selective agonists and antagonists revealed that different prostanoid receptors regulate the immune response at various steps by exerting often opposing actions 46, 50, 54, 55 , indicating that selective manipulation of each receptor's signaling may beneficially control immune responses. Given the in vivo effect of an EP4 antagonist on both T H 1 and T H 17 in CHS and EAE shown in this study, we propose EP4 as a promising drug target for immunomodulation. Quite recently, stimulatory action of PGE 2 on T H 17 differentiation or expansion in vitro was reported in human peripheral blood mononuclear cells 56, 57 . Thus, our findings will probably extend to pathological conditions in various immune diseases in humans.
METHODS
Methods and any associated references are available in the online version of the paper at http://www.nature.com/naturemedicine/.
Note: Supplementary information is available on the Nature Medicine website.
